Log In or Create Account
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Topics in Antiviral Medicine
™
February/March 2023
Volume 31, Issue 1
Download here
, or select individual articles
Claim CME
Invited Reviews
Providing Gender-Affirming Care to Transgender and Gender-Diverse Individuals With and at Risk for HIV
Olivia T. Van Gerwen, MD, MPH, Jill S. Blumenthal, MD, MAS
Chronic Hepatitis B and HIV Coinfection
Maria A. Corcorran, MD, MPH, H. Nina Kim, MD, MSc
Exploring Bacteriophage Therapy for Drug-Resistant Bacterial Infections
Robert T. Schooley, MD
Topics in Antiviral Medicine™
Current Issues
Previous Issues
TAM
Policies and Practices
TAM
Author and Contributor Guidelines
Topics in Antiviral Medicine
Editorial Board
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
April 15, 2024: Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Preexposure Prophylaxis
Which of the following statements about long-acting injectable cabotegravir (CAB-LA) for HIV preexposure prophylaxis is TRUE?
A. CAB-LA is less effective in the setting of active bacterial sexually transmitted infections
B. Every 2-month thigh injections of CAB-LA resulted in similar pharmacokinetics to every 2-month gluteal injections
C. During CAB-LA follow-up, the combination of a rapid HIV test and antigen/antibody test or 2 rapid tests that give the same result (eg, both positive or both negative) had high positive and negative predictive values
D. Integrase strand transfer inhibitor resistance mutations are unlikely to emerge in the setting of breakthrough infections with CAB-LA
Register Now
View Archived Questions
Leave Feedback
Subscribe
CLOSE
